Scribe Therapeutics (SCTX) Targets $100 Million IPO
Clinical-stage gene editing company looks to redefine cardiovascular care with proprietary CRISPR technologies designed for durable, scalable...
128 Views
Scribe Therapeutics Inc. (SCTX): Small Cap CRISPR Biotech Sets Terms Seeking $100m Raise
​Scribe Therapeutics poised to revitalize biotech IPOs with CRISPR-focused offering backed by strategic investors, targeting cardiovascular markets...
113 Views
Scribe Therapeutics (SCTX US): Synthetic Expert Call Transcript (13 Jul 2026)
Scribe's lead asset, STX-1150, represents a high-stakes clinical bet on transiently delivered epigenetic silencing over permanent gene editing,...
84 Views
Scribe Therapeutics Inc. (SCTX): Peeking at the IPO Prospectus of a Biotech Using CRISPR Technology
​CRISPR company Scribe targets cardiometabolic diseases with lead candidate advancing to human trials for LDL cholesterol reduction, backed by...
149 Views
Apnimed Inc. (APMD): "Waking Up" To the Next Late-Stage Biotech Story
​Late-stage biotech company set for FDA review of potential first oral therapy for obstructive sleep apnea, IPO oversubscribed with reduced...
149 Views